Use of Cardiovascular Disease Secondary Prevention Medications in Four Middle East Countries in a Community Setting
Global Heart2024Vol. 19(1), pp. 70–70
Citations Over TimeTop 10% of 2024 papers
Afzalhussein Yusufali, Marwan Zidan, Rasha Khatib, Roya Kelishadi, Khalid F. AlHabib, Mariam AlShamsi, A Rais, Afra Khalid Bintouq, Ahmad Bahonar, Noushin Mohammadifard, Mostafa Al Shamiri, Sumathy Rangarajan, Hamda Khansaheb, Salim Yusuf
Abstract
The use of secondary prevention medication is low in ME and has not reached the modest recommended WHO target of 50% use of 3 or more medications. Independent factors of higher use were, better socioeconomic status (household wealth, country wealth and education) and better contact and accessibility to health care (increasing age, female gender, obesity, diabetes and hypertension).
Related Papers
- → Interleucinas na encefalopatia hipóxico-isquêmica(2003)14 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)